Antisense IncRNA NNT-AS1 promotes esophageal squamous cell carcinoma progression by regulating its sense gene NNT expression

Xianglong Pan1,2, Qi Wang1,2, Yue Yu1, Weibing Wu1, Liang Chen1, Wei Wang1,2 and Zhihua Li1,2

© The Author(s) 2022

Antisense IncRNAs were endogenous productions from the antisense strand of coding genes and were transcribed in the reverse direction of the sense gene. The purpose of this study was to evaluate the roles and functions of antisense IncRNAs in esophageal squamous cell carcinoma (ESCC). Differentially expressed antisense IncRNAs were initially screened based on transcriptome data of 119 paired ESCC samples in GSE3624 and were further validated in 6 paired ESCC samples from our institution. Log-rank test was adopted to identify ESCC prognosis-associated IncRNAs. Finally, functional assays were performed to reveal the functions of our identified antisense IncRNAs. In total, 174 antisense IncRNAs were differentially expressed in both GSE3624 and JSPH databases. Of the five of them were significantly associated with ESCC prognosis (NNT-AS1, NKILA, CCDC18-AS1, SLC04A1-AS1, and AC110619.1). Note, NNT-AS1 showed the most significant association with ESCC prognosis. The upregulation of NNT-AS1 was further confirmed in ESCC cells. Knockdown of NNT-AS1 inhibited ESCC cell proliferation, migration, promoted ESCC cell apoptosis, and induced cell cycle arrest in the G2/M stage. NNT-AS1 expression significantly correlated with its sense gene NNT. As expected, NNT-AS1 knockdown suppressed NNT expression. Inhibition of NNT repressed ESCC cell proliferation and migration, and accelerated ESCC cell apoptosis. Overexpression of NNT could rescue the suppressed proliferation and migration of ESCC cells induced by the silencing of NNT-AS1. In terms of mechanism, NNT-AS1 served as a competing endogenous RNA to sponge the miR-382-5p, which could inhibit NNT expression. Pathway enrichment analysis and western blot assay indicated that NNT-AS1 and NNT could regulate the cell cycle pathway. In conclusion, antisense IncRNA NNT-AS1 facilitated ESCC progression by targeting its sense gene NNT through sponging miR-382-5p. This study provided us with a deeper insight into the roles of antisense IncRNAs in ESCC and identified novel potential therapeutic targets.

Cell Death Discovery (2022) 8:424; https://doi.org/10.1038/s41420-022-01216-w

INTRODUCTION

Esophageal cancer is one of the most diagnosed and death-caused malignant tumors around the world. As estimated, there were about 604 thousand new esophageal cancer cases (ranked seventh) and 544 thousand new deaths caused by esophageal cancer (ranked sixth) in 2020 [1, 2]. In contrast to the epidemic of esophageal adenocarcinoma in European countries, Esophageal squamous cell carcinoma (ESCC) is the most prevalent subtype in eastern Asia, eastern and southern Africa [3]. The prognosis of ESCC is poor with a five-year overall survival rate less than 30% in most countries [4, 5]. Therefore, doctors and researchers have to find novel diagnostic and therapeutic targets for ESCC.

Long non-coding RNAs (lncRNAs) could contribute to the development and progression of malignant tumors through multiple mechanisms [6, 7]. lncRNAs can be classified into several categories based on their positions relative to protein-coding regions: long intergenic noncoding RNAs, natural antisense transcripts, overlapping transcripts, bidirectional lncRNAs, and sense intronic lncRNAs [8]. Antisense lncRNAs are endogenous productions in nature that formed from the antisense strand of coding genes and transcribed in the opposite direction. They overlapped with sense genes or regulatory regions and could function both in cis or trans [9, 10]. Antisense lncRNAs could regulate protein-coding sense genes through the following mechanisms: transcriptional collision, gene recombination, promoter inactivation, alternative splicing, miRNA binding sites blocking, and endogenous siRNA formation [11–13]. For example, FOXP4-AS1 sponged miR-3184-5p to upregulate its host gene FOXP4 in prostate cancer [14]. SATB2-AS1 could cis-activate SATB2 transcription by decreasing the methylation level of SATB2 promoter in prostate cancer [15].

In ESCC, a few antisense IncRNAs that promoted or suppressed the tumorigenesis and progression of ESCC have been identified in previous studies. For example, silencing of ZEB1-AS1 inhibited the expression of ZEB1 and suppressed ESCC progression [16]. EZR-AS1 could facilitate ESCC cell growth by positively regulating the expression of EZR via interacting with methyltransferase SMYD3 [17]. ZNF667-AS1 repressed ESCC cell proliferation and invasion by upregulating ZNF667 expression via interacting with TET1 and UTX, which could decrease histone H3K27 trimethylation.

1Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 2These authors contributed equally: Xianglong Pan, Qi Wang. 3Email: wangwei15261883958@163.com; lizhihua_njmu@126.com

Received: 21 March 2022 Revised: 9 October 2022 Accepted: 11 October 2022
Published online: 21 October 2022
to activate ZNF667 [18]. KLF3-AS1 functioned as a tumor suppressor in ESCC by sponging miR-185-5p and decreased its suppression on the expression of KLF3 [19]. All these studies suggested the vital roles of antisense lncRNAs and their sense genes in ESCC. However, no study has systematically evaluated the roles of antisense lncRNAs in ESCC progression.

Therefore, we performed a systematic evaluation on the roles and functions of antisense lncRNAs in the progression of ESCC. Firstly, differentially expressed antisense lncRNAs (Annotated using Gencode V29) were screened using transcriptome profiles from GSE53624 and were validated in 6 paired ESCC samples from our Jiangsu Province Hospital (JSPH, Jiangsu, China) database. Then, the log-rank test was adopted to assess the associations between promising antisense lncRNAs and ESCC prognosis. Finally, functional assays were carried out to reveal the functions of our identified antisense lncRNA.

RESULTS

NNT-AS1 was aberrantly expressed in ESCC and was correlated with a poorer ESCC survival

Antisense lncRNAs annotation was performed based on Gencode V29. In total, 1386 promising antisense lncRNAs were initially screened in GSE53624. Among them, 174 lncRNAs were validated in our JSPH samples (Fig. S1). Five of them were significantly associated with ESCC prognosis: NNT-AS1, NKILA, CCDC18-AS1, SLC04A1-AS1, AC110691.1 (Fig. 1a, S2, S3). Notably, NNT-AS1 showed the most robust correlation with the overall survival of ESCC patients. NNT-AS1 was abnormally expressed in ESCC tumor tissues in both GSE53624 (Fig. 1b) and JSPH databases (Fig. 1c). A higher expression of NNT-AS1 in ESCC patients indicated a worse prognosis (Fig. 1d). Likewise, NNT-AS1 expression was upregulated in ESCC cell lines compared with HECEC (Fig. 1e).

Knockdown of NNT-AS1 suppressed ESCC progression

To reveal the functions of NNT-AS1, two siRNAs were used to knock down NNT-AS1. The knockdown efficiency was shown in Fig. 2a. NNT-AS1 knockdown induced decreased colony formation (Fig. 2b) and suppressed ESCC cell viability (Fig. 2c). Likely, suppression of NNT-AS1 inhibited ESCC cell proliferation rate according to the EdU assays (Fig. 2d). Besides, NNT-AS1 inhibition induced the G2/M arrest in both Eca-109 and Kyse-30 cell lines (Fig. 2e). In addition, cell apoptosis assays demonstrated that the apoptosis rate of ESCC cells was increased after silencing NNT-AS1 (Fig. 2f). Furthermore, NNT-AS1 suppression inhibited the migration of ESCC cells (Fig. 2g). Taken together, NNT-AS1 knockdown restrained ESCC cell proliferation, migration, caused ESCC cell arrest, and facilitated cell apoptosis.

NNT-AS1 positively regulated the expression of its sense gene NNT, which served as an oncogene in ESCC as well

Considering that NNT-AS1 was the antisense lncRNA of NNT, we wondered whether NNT-AS1 expression was correlated with that of NNT. As shown in Fig. 3a, NNT-AS1 expression significantly positively correlated with its sense gene NNT (r = 0.915, P < 0.001). NNT expression was also aberrantly upregulated in ESCC tumor tissues (Fig. 3b, c, GSE53624 and JSPH). Similarly, the high expression of NNT contributed to an inferior ESCC prognosis in combined datasets of GSE53624 and GSE53622 (Fig. 3d, HR = 1.44 (1.01-2.11), P = 0.031). Consistent with tissue samples, NNT was notably upregulated in ESCC cells (Fig. 3e). To demonstrate the influence of NNT-AS1 on NNT expression, we knocked down NNT-AS1 and detected the NNT expression. As expected, NNT-AS1 silencing significantly suppressed NNT expression in mRNA level (Fig. 3f), as well as in the protein level (Fig. 3g), suggesting that NNT-AS1 could regulate its sense gene NNT expression.

To reveal the functions of NNT in ESCC, three siRNAs were synthesized to knock down the expression of NNT (Fig. 4a). MTT, colony formation, and EdU assays indicated that NNT knockdown significantly inhibited the proliferation of ESCC cells (Fig. 4b–d). Transwell assay showed that inhibition of NNT suppressed ESCC cell migration (Fig. 4e). Furthermore, inhibition of NNT increased the apoptosis rate of ESCC cells (Fig. 4f). All the findings revealed that NNT functioned as a carcinogene in the tumorigenesis and development of ESCC.

NNT-AS1 could sponge the miR-382-5p in ESCC

LncRNA-miRNA-mRNA axis was a crucial mechanism through which lncRNAs influenced the tumorigenesis and progression of malignant tumors [20, 21]. We predicted the NNT-mediated miRNA using the ENCORI database, and 49 miRNAs were screened. Subsequently, we analyzed the differentially expressed miRNAs based on the GSE114110 database. As a result, six of them were markedly downregulated, including miR-382-5p, miR-26a-5p, miR-26b-5p, miR-186-5p, miR-130a-3p, and miR-582-5p. Among them, the foldchange of miR-382-5p ranks first. Additionally, a previous investigation manifested that miR-382 could suppress tumor progression against ESCC [22]. Thus, we hypothesized that NNT-AS1 might regulate NNT expression through sponging miR-382-5p. Figure 5a illustrated the predicted binding site of NNT-AS1 and miR-382-5p by Starbase. As anticipated, miR-382-5p expression was apparently decreased in ESCC (Fig. 5b, c). Figure 5d showed the transfection efficacies of miR-382-5p mimics and inhibitors. The miR-382-5p mimics significantly inhibited NNT-AS1 expression (Fig. 5e). Knockdown of NNT-AS1 led to increased miR-382-5p expression (Fig. 5f). Further, dual-luciferase reporter assays indicated that miR-382-5p overexpression weakened the luciferase activity in the NNT-AS1-WT group (Fig. 5g). Furthermore, the rescue assays demonstrated that miR-382-5p inhibition partially rescued the declined proliferation and migration abilities of ESCC cells mediated by NNT-AS1 knockdown (Fig. 5h–j).

NNT was regulated by miR-382-5p and retrieved the decreased cell functions mediated by NNT-AS1 silence

The predicted binding locus of miR-382-5p and NNT was shown in Fig. 6a. Co-transfection with NNT-WT and miR-382-5p mimics in Eca-109 weakened the luciferase activity compared to NNT-WT and miR-NC, while NNT-Mut failed to induce such a reduction. In contrast, NNT-WT and miR-382-5p inhibitor co-transfection led to increased luciferase activity in comparison with the miR-NC (Fig. 6b). Further, inhibition of miR-382-5p partly retrieved the decreased NNT expression in both mRNA and protein levels induced by NNT-AS1 knockdown (Fig. 6c, d). NNT overexpression facilitated ESCC cell proliferation and migration. As expected, overexpression of NNT could counteract the suppressed ESCC cell proliferation induced by NNT-AS1 inhibition (Fig. 6e–g). Furthermore, NNT rescued the increased apoptosis rate generated by NNT-AS1 suppression (Fig. 6h). NNT upregulation also recovered cell migration that declined by NNT-AS1 knockdown (Fig. 6i). Taken together, NNT-AS1 facilitated ESCC tumorigenesis and process by modulating its sense gene NNT expression.

NNT-AS1 promoted ESCC cell growth in vivo by regulating the cell cycle signaling pathway

The role that NNT-AS1 played in the tumor growth of ESCC was further evaluated by the xenograft model. As shown in Fig. 7a, b, mice with Eca-109 cells stably transfected with shNNT-AS1 had a smaller tumor volume than the shCtrl group. In line, compared to mice in the shCtrl arm, those in the shNNT-AS1 group exhibited a lower tumor weight (Fig. 7c). Moreover, the Ki-67 positivity was markedly decreased in tumors formed from Eca-109 cells transfected with shNNT-AS1 (Fig. 7d). All the findings suggested that the silence of NNT-AS1 could suppress ESCC tumor growth in vivo.

To suggest the potential down-stream pathway through which NNT contributed to ESCC tumorigenesis and progression, pathway...
enrichment analysis was performed. As shown in Fig. 7e, NNT might participate in multiple signaling pathways, including the cell cycle pathway, one of the central pathways in cancers. This result was consistent with the above flow cytometry findings. Western blot assays indicated that NNT-AS1 and NNT silencing could suppress the levels of CCNB1, CCNB2, CDK1, and CDK2 (Fig. 7f). Taken together, NNT-AS1 contributed to ESCC initiation and development through regulating the cell cycle pathway.

DISCUSSION

In this study, we evaluated the roles of antisense lncRNAs in ESCC through a systematic analysis. As a result, NNT-AS1 was found aberrantly upregulated in ESCC and was significantly associated with a poorer prognosis. Functionally, we found that NNT-AS1 might contribute to ESCC progression through positively regulating its sense gene NNT expression by sponging miR-382-5p.

NNT-AS1, located in 5p12, has been verified to play a carcinogenic role in multiple malignant tumors, including lung squamous cell carcinoma, cervical cancer, gastric cancer, and so on. Ma et al. discovered that NNT-AS1 accelerated the progression of lung squamous cell carcinoma by positively modulating FOXM1, a member of the FOX transcription factor family [23]. Li et al. revealed that NNT-AS1 facilitated breast cancer progression by regulating ZEB1 expression through sponging miR-142-3p [24]. Chen and colleagues demonstrated that NNT-AS1 could contribute to the tumorigenesis of gastric cancer by targeting E2F1 which served as a transcription factor and was an important regulator in cell cycle [25]. Nevertheless, the functions and roles of NNT-AS1 in ESCC remained unclear. NNT-AS1 was found aberrantly expressed in ESCC and showed a significant association with a poorer survival of ESCC for the first time. Functionally, silencing of NNT-AS1 restrained ESCC cell proliferation and migration. Besides, NNT-AS1 inhibition could induce the arrest of G2/M phase in cell cycle progression and promote ESCC cell apoptosis. Tumor xenograft experiment in nude mice indicated that silencing of NNT-AS1 slackened the tumor growth in vivo. All these results manifested that NNT-AS1 could promote the tumorigenesis and progression of ESCC. However, which was the target gene of NNT-AS1, and what was the molecular mechanism underlying NNT-AS1’s functions in ESCC?

Considering that NNT was the sense gene of NNT-AS1 and regulating the sense gene expression was a vital mechanism through which antisense lncRNAs modulated tumorigenesis and progression, we analyzed the correlation between NNT-AS1 and NNT. Strikingly, the expression of NNT was significantly correlated with NNT-AS1 expression, suggesting that NNT-AS1 might regulate NNT expression. As expected, knockdown of NNT-AS1 significantly suppressed NNT expression. Functionally, NNT encoded an integral protein of the inner mitochondrial

Fig. 1 NNT-AS1 was aberrantly upregulated in ESCC and associated with poorer ESCC prognosis. a The screening process of NNT-AS; b, c NNT-AS1 expression was upregulated in ESCC tissues (b GSE53624, c JSPH, paired Student’s t-test); d high expression of NNT-AS1 was significantly associated with an inferior ESCC prognosis (Log-rank test); e the expression level of NNT-AS1 in ESCC cell lines (Eca-109, Kyse-30, and TE-1) was significantly higher than that in the human normal esophageal epithelial cell line (HEEC) (unpaired Student’s t-test). The results were from three independent experiments. ***P < 0.001, **P < 0.01. Variables were presented as the Mean ± SD (Standard Deviation).
membrane. Previous studies showed that NNT served as an oncogene in multiple cancers. For example, knockdown of NNT significantly suppressed gastric cancer growth and metastasis through the oxidative stress pathway [26]. NNT could regulate mitochondrial metabolism in lung cancer by maintaining the function of the Fe-S protein [27]. Nevertheless, the roles of NNT in ESCC progression have not been revealed. In this study, we observed that the silence of NNT exerted inhibitory effects on the growth and migration of ESCC cells, while NNT overexpression partially retrieved the decreased proliferation and migration abilities induced by NNT-AS1 inhibition. Highlighting these findings, we speculated that NNT-AS1 could modulate ESCC tumorigenesis and progression by regulating its sense gene NNT.

Given that ceRNA was a common mechanism through which lncRNAs regulated the target genes [28, 29], we predicted the potential miRNAs that could interact with NNT-AS1. Consequently,
miR-382-5p was determined as the candidate miRNA due to its potential of binding to NNT-AS1 and aberrant expression in ESCC. Through dual-luciferase assays, we verified that miR-382-5p could combine with NNT-AS1 and NNT. MiR-382-5p inhibition retrieved the decreased NNT expression that NNT-AS1 knockdown mediated in ESCC cell lines. Functionally, rescue experiments further validated that miR-382-5p suppression reversed the inhibitory impacts of NNT-AS1 knockdown on ESCC progression. Additionally, miR-382-5p was reported to suppress ESCC progression and was associated with a favorable prognosis in previous studies [22, 30]. All the findings above suggested that NNT-AS1 acted as a ceRNA by sponging miR-382-5p to regulate its sense gene NNT.

The cell cycle signaling pathway was crucial in the development of malignant tumors [31, 32]. This study found that NNT-AS1 knockdown induced the G2/M arrest in ESCC cell lines. Besides, pathway enrichment analysis indicated that NNT might participate in the modulation of the cell cycle signaling pathway in ESCC. Western blot assays further confirmed that inhibition of NNT and NNT-AS1 suppressed the expression levels of CDK1, CDK2, CCNB1, and CCNB2, all of which were vital proteins in the cell cycle signaling pathway. Taken together, these findings suggested that NNT-AS1 and NNT could promote ESCC progression by regulating the cell cycle signaling pathway.

**CONCLUSIONS**

Antisense IncRNA NNT-AS1 promoted ESCC progression by targeting its sense gene NNT through competitively sponging miR-382-5p. This study provided us with a deeper insight into the roles of antisense IncRNAs in ESCC and identified novel potential therapeutic targets.

**MATERIALS AND METHODS**

**Tissue samples and transcriptome sequencing**

Six paired ESCC tumor-normal tissues were obtained from JSPH. Total RNA was extracted from the samples. Then ribosomal RNAs were removed by TruSeq StrandedTotal RNA with Ribo-Zero Gold Kit (Illumina, San Diego,
Annotation and screening of antisense IncRNAs

The GENCODE project provided comprehensive and detailed annotations for the human and mouse genomes [33]. In this study, we obtained the IncRNA annotation from GENCODE (GenCode V29, https://www.gencodegenes.org/). There were 5587 IncRNAs annotated as antisense IncRNAs according to the GenCode V29. The GSE53624 dataset that contained IncRNA and mRNA expression profiles of 119 paired ESCC tumor-normal samples was used for differential antisense IncRNAs screening. After annotation, 2003 antisense lncRNAs were obtained from GENCODE (Gencode V29, https://www.gencodegenes.org/).

Cell culture and transfection

Human ESCC cell lines (Kyse-30, Eca-109, and TE-1) and human normal esophageal epithelial cell line (HEEC) were purchased from iCell Bioscience, Shanghai, China. RPMI-1640 medium (Gibco, Rockville, Maryland, USA) with 10% fetal bovine serum (FBS; Biological Industries, Israeli), penicillin-G (100 U/ml), and streptomycin (100 g/ml) (Gibco, Rockville, Maryland, USA) was used for Kyse-30 and TE-1 incubation. DMEN (Gibco, Rockville, Maryland USA) contains the same ingredients were used for Eca-109 and HEEC. The cultivation environment was man-made at 37 °C with 5% CO2. The sequence of transfected RNAs together with the name of suppliers were listed in Table S1. For overexpression of NNT, the cDNA encoding NNT was amplified and cloned into the pcDNA3.1 vector (Invitrogen, Carlsbad, New Mexico, USA) to form NNT overexpression plasmid. Transfections were carried out using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) following instructions.

Quantitative Real-time PCR (qRT-PCR)

The cell lines at the period of logarithmic growth were transfected. Then the total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) 48 h later. The extracted RNAs were reversely transcribed to cDNAs using PrimeScriptTM II Reverse Transcriptase (Takara, Tokyo, Japan). Gene expression was calculated as previously reported [34]. Primer sequences were illustrated in Table S1.

MTT assay

2 × 10^4 transfected cells were planted in a 96-well plate per well. At different checking points (0, 24, 48, 72, and 96 h), the cells were incubated in a complete medium with 20 μL MTT (concentration: 0.5 mg/mL) for 4 h. Then DMSO (150 μL per well) was used to dilute the formazan that formed from MTT. After 10 min incubation, the cell viability was measured at the absorbance of 490 nm.

Fig. 4 Knockdown of NNT suppressed ESCC cell proliferation and migration. a The knockdown efficiency of short interfering RNAs for NNT was measured in Eca-109 and Kyse-30; b-d Knockdown of NNT inhibited proliferation of Eca-109 and Kyse-30 cells using MTT assays, colony forming assays, and EdU assays; e Knockdown of NNT inhibited the migration of Eca-109 and Kyse-30 cells; f Knockdown of NNT increased the apoptotic rate of both ESCC cell lines. The results were from three independent experiments. Data were analyzed by unpaired Student’s t-test. ***P < 0.001, **P < 0.01, *P < 0.05. Variables were presented as the Mean ± SD.
a) 5' gcagACTGGAGCAAG-AACAAGTTga 3' NNT-AS1 WT
6' ctgcUAGGUGGGGCUGUGUGAAga 5' miR-382-5p
6' gcagTTACTTAGTGC-TAGTAGAga 3' NNT-AS1 MUT

b) Colony forming assay
2 × 10⁵ transfected cells were planted in a 6-well plate per well and incubated in a complete medium until the colonies could be detected by naked eyes. Then the colonies were cleaned with normal saline and fixed with 4% paraformaldehyde (room temperature, 15 min) followed by staining using 0.5% crystal violet staining (Beyotime, Shanghai, China). ImageJ software was used to detect the number of colonies.

5-Ethynyl-2'-deoxyuridine (EdU) assay
A total of 1 × 10⁵ transfected cells were added evenly in 96-well plate per well and incubated for two days. EdU assays were performed using 1′Ethynyl-5′-Click-iT EdU Imaging Kits (US EVERBRIGHT, China) under the instruction of the manufacturer. The treated cells were detected under an inverted fluorescence microscope and the graphs were captured simultaneously from three random fields. The proliferation rate in EdU staining was defined as the percentage of EdU staining cells relative to cells stained by DAPI.

Transwell assay
Transwell assays were carried out using Transwell apical chamber (Corning Life Sciences, Corning, NY, USA). In total, 5 × 10⁴ transfected cells were added into the upper compartment, while 700 µl complete medium was injected into the lower part. After 24 h, cells were fixed using 4% paraformaldehyde followed by staining with 0.5% crystal violet. Then, cells that failed to migrate to the outer surface of the upper compartment were scrubbed by cotton swabs. Five microscopic fields per chamber were
Fig. 6 MiR-382-5p negatively regulated NNT and overexpression of NNT rescued the decline of cellular function that NNT-AS1 knockdown mediated in ESCC. a MiR-382-5p had a binding site for NNT; b Dual-Luciferase assays were utilized to detect the luciferase activities in Eca-109 cells after being co-transfected with miRNAs (miR-NC, miR-382-5p mimics, miR-382-5p inhibitor) and luciferase reporter vectors (NNT- WT and NNT- MUT) respectively; c, d downregulation of miR-382-5p rescued the decreased NNT expression mediated by NNT-AS1 inhibition in Eca-109 and Kyse-30 cells; e–i Rescue assays were conducted to measure the cellular functions of NNT-AS1 knockdown cells after overexpressing NNT in Eca-109 and Kyse-30 cells. The results were from three independent experiments. Data were analyzed by unpaired Student’s t-test. ***P < 0.001, **P < 0.01, *P < 0.05. Variables were presented as the Mean ± SD.
observed for counting the migratory cells (at ×100 magnification). The count of migratory cells was performed using ImageJ software.

Flow cytometry assays
A total of 5 × 10⁶ cells were cultured and transfected. 48 h after transfection, the collected adherent cells were fixed in 75% ethanol followed by staining with PI. Cell apoptosis assay was carried out according to the protocol of the Annexin V-FITC and PI Apoptosis Kit (US EVERBRIGHT, China). The results were assessed by FACScalibur (BD, Franklin Lakes, NJ, USA). FlowJo software 10.8.0 (BD, Franklin Lakes, NJ, USA) was used to perform the analysis.

Dual-luciferase assay
The potential binding sites of miR-382-5p in NNT-AS1 and NNT were illustrated in Table S2. In brief, Eca-109 cells were infected with lentivirus-coated shNNT-AS1 and shCtrl, which respectively transduced Eca-109 cells, which were respectively injected into the back of nude mice; the tumor weight in the shCtrl group was higher than that in the shNNT-AS1 group; the tumor sections were undergone ki-67 staining and HE staining; pathway enrichment analysis was conducted to predict the potential pathways that NNT participated in ESCC; several checkpoints of cell cycle pathway were measured using western blot assays after silencing NNT and NNT-AS1. The results were from three independent experiments. Data were analyzed by unpaired Student's t-test. ***P < 0.001, **P < 0.01, *P < 0.05. Variables were presented as the Mean ± SD.

Western blot assay
Proteins were extracted and quantified using RIPA lysis buffer (Beyotime, Shanghai, China) and BCA Protein Assay kit (Thermo Fisher Scientific, Waltham, MA, USA), respectively. The proteins with loading buffer (volume ratio = 1:4) were added in lanes of 4–20% SurePAGE (GeneScript, Nanjing, Jiangsu, China). After electrophoresis, the protein gel was transferred to the PVDF membrane (Millipore, Massachusetts, USA) and blocked using 5% skimmed milk in TBST. Then, the membranes were incubated in specific antibodies as follows: GAPDH (AC001, 1:2000) NNT (A4561, 1:500), CDK1 (A0220, 1:1000), CDK2 (A38000, 1:1000), CCNB1 (A19037, 1:1000), and CCNB2 (A3351, 1:1000). All the antibodies mentioned above were purchased from Abcolonal, Wuhan, China. GelDoc XR + (Bio-Rad, Hercules, CA, USA) was adopted to develop the protein bands.

Animal experiment
Stably transfected Eca-109 cells with NNT-AS1 silence (shNNT-AS1) and negative control (shCtrl) were constructed for animal experiments. The sequence of shNNT-AS1 was illustrated in Table S2. In brief, Eca-109 cells were infected with lentivirus-coated shNNT-AS1 and shCtrl, which contained the green fluorescent protein. The transfection efficiency was assessed through observing the fluorescence intensity under a fluorescence microscope and qRT-PCR was utilized for accurate evaluation.

Six 6 weeks old nude male mice were purchased from Weitonglihua, Beijing, China. The stably transfected Eca-109 cells were inoculated into the back of the mice, right for shNNT-AS1 and left for shCtrl respectively. The diameter of the tumor was measured and recorded every 3 days. The volume of the tumor was determined as: \( V = \frac{1}{2} \times (L D \times (SD)^2) \) (LD: the largest diameter; SD: the shortest diameter). The nude mice were euthanized on the 15th day through cervical dislocation and the tumors were dissected and weighed. All animal experiments were performed under the protocols approved by the Experimental Animals Ethics Committee of Nanjing Medical University.

Statistical analysis
In this study, paired student’s t-test was adopted for the comparison of IncRNA expression in ESCC tumor and adjacent normal tissues. The false discovery rate (FDR) was used to correct the P values. Associations between IncRNA expression and ESCC prognosis were assessed using the Log-rank test. The unpaired student’s t-test was applied to test the differences between experimental groups. The expression relationship between NNT-AS1 and NNT was assessed based on Pearson correlation. Statistical tests were conducted based on R 3.6.0 and Graphpad Prism 8.0. The statistical significance level was set at P < 0.05.

DATA AVAILABILITY
The datasets used and analyzed in this study are available from the corresponding author on reasonable request.

REFERENCES
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J Clinicians. 2021;71:209–49.
2. Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159:329–49.
10

X. Pan et al.

3. Abnet CC, Arnold M, Wei QO. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154:360–73.
4. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust TA, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURMARK-2): a population-based study. Lancet Oncol. 2019;20:1493–505.
5. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikllec M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registers in 71 countries. Lancet. 2018;391:1023–75.
6. Chan JY, Tai Y. Noncoding RNA/RNA regulatory networks in cancer. Int J Mol Sci. 2018;19:1310.

7. Bach DH, Lee SK. Long noncoding RNAs in cancer cells. Cancer Lett. 2018;419:152–66.

8. Knauß JL, Sun T. Regulatory mechanisms of long noncoding RNAs in vertebrate central nervous system development and function. Neuroscience. 2013;235:200–14.

9. Villegas VE, Zaphiropoulos PG. Neighboring gene regulation by antisense long non-coding RNAs. Int J Mol Sci. 2015;16:3231–66.

10. Xu JZ, Zhang J, Zhang W. Antisense RNA: the new favorite in genetic research. J Zhejiang Univ Sci B. 2018;19:739–49.

11. Magistri M, Faghihi MA, Laurent G, Wahlestedt C. Regulation of chromatin structure by long noncoding RNAs: focus on natural antisense transcripts. Trends Genet. 2012;28:389–96.

12. Zhou M, Guo X, Wang M, Qin R. The patterns of antisense long non-coding RNAs regulating corresponding sense genes in human cancers. J Cancer. 2021;12:1499–506.

13. Werner A. Biological functions of natural antisense transcripts. BMC Biol. 2013;11:655–73.

14. Wu X, Xiao Y, Zhou Y, Zhou Z, Yan W. LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4. Cell Death Dis. 2019;10:472.

15. Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Oncol. 2019;13:183.

16. Zhao Y, Wang N, Zhang X, Liu H, Yang S. LncRNA ZEB1-AS1 down-regulation suppresses the proliferation and invasion by inhibiting ZEB1 expression in oesophageal squamous cell carcinoma. J Cell Mol Med. 2019;23:8206–18.

17. Zhang XD, Huang GW, Xie YH, He JZ, Guo JC, Xu XE, et al. The interaction of IncRNA EZR-AS1 with Smyd3 maintains overexpression of EZR in ESCC cells. Nucleic Acids Res. 2018;46:1793–809.

18. Dong Z, Li S, Wu X, Niu Y, Liang X, Yang L, et al. Aberrant hypermethylation-mediated downregulation of antisense IncRNA ZNF667-AS1 and its sense gene ZNF667 correlate with progression of esophageal squamous cell carcinoma. Cell Death Dis. 2019;10:930.

19. Liu JQ, Deng M, Xue NN, Li TX, Guo YX, Gao L, et al. IncRNA KLF3-AS1 suppresses cell migration and invasion in ESCC by impairing miR-185-5p-targeted KLF3 inhibition. Mol Ther Nucleic Acids. 2020;20:231–41.

20. Lu YF, Yu JR, Yang GX, Guo P, Wang H, et al. Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXD3 to promote the progression of esophageal squamous cell carcinoma (ESCC). J Exp Clin Cancer Res. 2018;37:301.

21. Qi XL, Zhang DH, Wu N, Xiao JH, Wang X, Ma W. ceRNA in cancer: possible functions and clinical implications. J Med Genet. 2015;52:710–8.

22. Feng J, Qi B, Guo L, Chen LY, Wei XF, Liu YZ, et al. miR-382 functions as a tumor suppressor against esophageal squamous cell carcinoma. World J Gastroenterol. 2017;23:4243–51.

23. Ma J, Qi G, Li L. LncRNA NNT-AS1 promotes lung cancer squamous cell carcinoma progression by regulating the miR-22/FOXM1 axis. Cell Mol Biol Lett. 2020;25:354.

24. Li Y, Lv M, Song Z, Lou Z, Wang R, Zhuang M. Long non-coding RNA NNT-AS1 affects progression of breast cancer through miR-142-3p/ZEB1 axis. Biomed Pharmacother. 2018;103:939–46.

25. Chen B, Zhao Q, Guan L, Lv H, Bie L, Huang J, et al. Long non-coding RNA NNT-AS1 sponges miR-424/21 to promote the tumorigenesis and cell cycle progression of gastric cancer. J Cell Mol Med. 2018;22:4751–9.

26. Li S, Zhuang Z, Wu T, Lin JC, Liu ZX, Zhou LF, et al. Nicotinamide nucleotide transhydrogenase-mediated redox homeostasis promotes tumor growth and metastasis in gastric cancer. Redox Biol. 2018;18:246–55.

27. Nicolai KG, Karg YP, Falzone A, Boyle TA, DeNicola GM. Nicotinamide nucleotide transhydrogenase regulates mitochondrial metabolism in NSCLC through maintenance of Fe-S protein function. J Exp Med. 2020;217:e20191689.

28. Xu M, Chen X, Lin K, Zeng K, Liu X, Xu X, et al. IncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. J Hematol Oncol. 2019;12:3.

29. Cai Y, Zhao YS, Chen Y, Wang JY. LncRNA HMMR-AS1 promotes proliferation and metastasis of lung adenocarcinoma by regulating miR-138/itsh6 axis. Aging. 2019;11:3041–54.

30. Qi L, Lu J, Gao WJ, Chang TM, Qin XG, Ji YH. Downregulation of microRNA-382 is associated with poor outcome of esophageal squamous cell carcinoma. World J Gastroenterol. 2021;17:6884–91.

31. Huang L, Wang Y, Chen J, Wang Y, Zhao Y, Wang Y, et al. Long noncoding RNA PCAT1, a novel serum-based biomarker, enhances cell growth by sponging miR-326 in oesophageal squamous cell carcinoma. Cell Death Dis. 2019;10:513.

32. Wang B, Hang J, Li W, Yuan W. Knockdown of LncRNA DLEU2 inhibits cervical cancer progression via targeting miR-128-3p. Onco Targets Ther. 2020;13:10173–84.

33. Frankish A, Diekhans M, Ferreira AM, Johnson R, Jurisica I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47:D766–D773.

34. Geng X, Zhang Y, Lin X, Zeng Z, Hu J, Hao L, et al. Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma. Cell Death Dis. 2022;13:596.

ACKNOWLEDGEMENTS

This work was supported by the Young Scholars Fostering Fund of the First Affiliated Hospital of Nanjing Medical University (PY2021024), the Wujieping Medical Foundation (320.6750.2020-15-8), and the National Natural Science Foundation of China (81972172).

AUTHOR CONTRIBUTIONS

WWa and ZL conceived and designed the research; QW and XP performed the research, acquired the data, and wrote the original draft. YY, WWu, LC analyzed and interpreted the data, and supervised the draft. All authors were involved in drafting and revising the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41420-022-01216-w.

Correspondence and requests for materials should be addressed to Wei Wang or Zhihua Li.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022.